Association of Statin Use with the Risk of Incident Prostate Cancer: A Meta-Analysis and Systematic Review

Meng-Yao Xu,Ye An,Chen-Qian Liu,Jin-Zhou Xu,Xing-Yu Zhong,Na Zeng,Jian-Xuan Sun,Qi-Dong Xia,Shao-Gang Wang
DOI: https://doi.org/10.1155/2022/7827821
IF: 4.501
2022-12-14
Journal of Oncology
Abstract:Background. With the growth and aging of population, the incidence of prostate cancer will increase year by year, which is bound to bring greater economic burden to the society. There has been greater interest in the anticancer effects of statin in recent years. It is controversial whether statin use is associated with the risk of prostate cancer (PCa). Thus, we conducted a meta-analysis and systematic review to explore the effects of statin use and their duration and cumulative dose on the overall incidence of PCa. Method. The study was conducted according to the latest guidelines for PRISMA 2020. We searched PubMed and other databases for studies about the association of statin use with the risk of incident prostate cancer between January 1, 1990, and April 11, 2022. Two independent researchers extracted data and evaluated the quality of the studies. R x64 4.1.2 and random-effects model were used for data statistics. Relative risk (RR) and odds ratio (OR) effective values with a 95% confidence interval (95% CI) were used to assess the main results. Results. The results of 6 RCT and 26 cohort studies showed that statins did not significantly associate with the incidence of PCa (RR = 0.94, 95% CI: 0.82–1.08). The similar results were obtained from 9 case-control studies (OR = 1.03, 95% CI: 0.99–1.07). However, statins were associated with a lower risk of Pca (RR = 0.44, 95% CI: 0.28–0.70) when the cumulative defined daily dose (cDDD) was high. Using statins for more than five years could be associated with a reduced incidence of Pca (RR = 0.47, 95% CI: 0.23–0.97). There was a significant heterogeneity in these studies (RCT and cohort study: I2 = 98%, P < 0.01; case-control study: I2 = 72%, P < 0.01). Conclusion. We concluded that statins had a neutral association with the overall risk of PCa. High cDDD and long duration were associated with a lower risk of PCa.
oncology
What problem does this paper attempt to address?
The problem that this paper attempts to solve is to explore the relationship between statin use and the risk of prostate cancer. Specifically, the study aims to explore the impact of statin use, its duration, and cumulative dose on the overall incidence of prostate cancer through meta - analysis and systematic review methods. The paper focuses on whether statins can reduce the risk of prostate cancer and whether this effect varies depending on the type of drug, the length of use, or the cumulative dose. ### Background With the growth and aging of the population, the incidence of prostate cancer is increasing year by year, which will bring greater economic burdens to society. In recent years, there has been greater interest in the anticancer effects of statins. However, there is controversy regarding whether statin use is associated with the risk of prostate cancer. Therefore, this study explored the impact of statin use, its duration, and cumulative dose on the overall incidence of prostate cancer through meta - analysis and systematic review methods. ### Methods The study followed the latest PRISMA 2020 guidelines. Researchers searched PubMed and other databases for studies related to statin use and the risk of prostate cancer from January 1, 1990, to April 11, 2022. Two independent researchers extracted data and evaluated the quality of the studies. Data analysis was performed using R x64 4.1.2 and a random - effects model. Valid values of relative risk (RR) and odds ratio (OR) and their 95% confidence intervals (95% CI) were used to evaluate the main results. ### Results The results of 6 randomized controlled trials and 26 cohort studies showed that there was no significant association between statin use and the incidence of prostate cancer (RR = 0.94, 95% CI: 0.82 - 1.08). Similar results were obtained from 9 case - control studies (OR = 1.03, 95% CI: 0.99 - 1.07). However, when the cumulative defined daily dose (cDDD) was high, statins were associated with a lower risk of prostate cancer (RR = 0.44, 95% CI: 0.28 - 0.70). Using statins for more than 5 years may be associated with a reduction in the incidence of prostate cancer (RR = 0.47, 95% CI: 0.23 - 0.97). There was significant heterogeneity in these studies (randomized controlled trials and cohort studies: I² = 98%, P < 0.01; case - control studies: I² = 72%, P < 0.01). ### Conclusion The study concludes that statins have a neutral association with the overall risk of prostate cancer. High cDDD and longer use time are associated with a lower risk of prostate cancer.